Nodular regenerative hyperplasia: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
(Added new information about risk factors and pathophysiology. Summarised existing information into bullets.) |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Nodular regenerative hyperplasia is described as a rare form of non-cirrhotic [[portal hypertension]]. | Nodular regenerative hyperplasia is described as a rare form of non-cirrhotic [[portal hypertension]] in the absence of a recognizable cause. Nodular regenerative hyperplasia is associated with solid organ transplant (eg. renal transplants, [[Bone marrow transplantation|bone marrow transplant]]<nowiki/>s) and chronic use of medications. Nodular regenerative hyperplasia may be classified into 2 subtypes: pre-sinusoidal and sinusoidal.<ref name="pmid22956964">{{cite journal |vauthors=Louwers LM, Bortman J, Koffron A, Stecevic V, Cohn S, Raofi V |title=Noncirrhotic Portal Hypertension due to Nodular Regenerative Hyperplasia Treated with Surgical Portacaval Shunt |journal=Case Rep Med |volume=2012 |issue= |pages=965304 |year=2012 |pmid=22956964 |pmc=3432362 |doi=10.1155/2012/965304 |url=}}</ref> The pathogenesis of nodular regenerative hyperplasia is characterized by arterial hypervascularity secondary to loss of hepatic vein radicles and loss of central venule in the [[hepatic lobule]]. Nodular regenerative hyperplasia is a rare disease. The estimated incidence of nodular regenerative hyperplasia is approximately 0.34 cases per 100,000 individuals. Nodular regenerative hyperplasia is more commonly observed among patients between 25 and 65 years old.<ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> The majority of patients with nodular regenerative hyperplasia may be initially asymptomatic. Early clinical features include [[fatigue]], [[weight loss]], and [[abdominal distension]]. If left untreated, the majority of patients with nodular regenerative hyperplasia may progress to develop [[Acute liver failure|acute hepatic failure]] and death. The diagnosis of nodular regenerative hyperplasia is made with the following diagnostic criteria: latency of more than 6 months, minimal or no elevations in serum ALT, clinical, radiologic or endoscopic signs of portal hypertension, and [[liver biopsy]]. | ||
| Line 20: | Line 23: | ||
==Pathophysiology== | ==Pathophysiology== | ||
* The pathogenesis of nodular regenerative hyperplasia is characterized by | * It is a poorly understood disease process thought to be mediated by chronic inflammatory and thrombotic processes leading to occlusion of hepatic microvascuature.<ref>{{Cite journal|last=Vispo|first=E|date=May 2010|title=Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings.|url=https://www.ncbi.nlm.nih.gov/pubmed/20299955|journal=AIDS.|volume=|pages=|via=}}</ref> | ||
*The pathogenesis of nodular regenerative hyperplasia is characterized by: | |||
**Arterial hypervascularity secondary to loss of hepatic vein radicles | |||
**Loss of central venule in the hepatic lobule. | |||
* The RASSF1A gene has been associated with the development of nodular regenerative hyperplasia, involving the proapoptotic pathway.<ref name="librepato">Nodular regenerative hyperplasia. Libre Pathology https://librepathology.org/wiki/Medical_liver_disease#Nodular_regenerative_hyperplasia Accessed on April 12, 2015 </ref> | * The RASSF1A gene has been associated with the development of nodular regenerative hyperplasia, involving the proapoptotic pathway.<ref name="librepato">Nodular regenerative hyperplasia. Libre Pathology https://librepathology.org/wiki/Medical_liver_disease#Nodular_regenerative_hyperplasia Accessed on April 12, 2015 </ref> | ||
* On gross pathology:<ref name="librepato">Nodular regenerative hyperplasia. Libre Pathology https://librepathology.org/wiki/Medical_liver_disease#Nodular_regenerative_hyperplasia Accessed on April 12, 2015 </ref> | * On gross pathology:<ref name="librepato">Nodular regenerative hyperplasia. Libre Pathology https://librepathology.org/wiki/Medical_liver_disease#Nodular_regenerative_hyperplasia Accessed on April 12, 2015 </ref> | ||
| Line 37: | Line 43: | ||
* Neoplastic | * Neoplastic | ||
* Chronic use of medications, such as: | * Chronic use of medications, such as: | ||
**[[Azathioprine]] <ref name="pmid17504943">{{cite journal| author=Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D et al.| title=Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. | journal=Gut | year= 2007 | volume= 56 | issue= 10 | pages= 1404-9 | pmid=17504943 | doi=10.1136/gut.2006.114363 | pmc=2000290 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17504943 }}</ref> | **[[Azathioprine]] <ref name="pmid17504943">{{cite journal| author=Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D et al.| title=Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. | journal=Gut | year= 2007 | volume= 56 | issue= 10 | pages= 1404-9 | pmid=17504943 | doi=10.1136/gut.2006.114363 | pmc=2000290 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17504943 }}</ref><ref>{{Cite journal|last=Dubinksy|first=MC|date=August 2003|title=6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.|url=https://www.ncbi.nlm.nih.gov/pubmed/12891528/|journal=Gastroenterology|volume=125(2)|pages=298-303|via=}}</ref> | ||
** [[Thioguanine]] | ** [[Thioguanine]] | ||
** [[Mercaptopurine]] | ** [[Mercaptopurine]] | ||
| Line 45: | Line 51: | ||
** [[Vitamin A]] | ** [[Vitamin A]] | ||
** [[Methotrexate]] | ** [[Methotrexate]] | ||
**Trastuzumab<ref>{{Cite journal|last=Lepelley|first=Marion|date=November-December 2018|title=Nodular Regenerative Hyperplasia Induced by | |||
Trastuzumab Emtansine: Role of Emtansine?|url=https://www.medigraphic.com/pdfs/hepato/ah-2018/ah186u.pdf|journal=Annals of Hepatology|volume=17|pages=1067-1071|via=}}</ref> | |||
* NRH is commonly found in patients with Abernethy’s Syndrome. | |||
==Differentiating nodular regenerative hyperplasia from other Diseases== | ==Differentiating nodular regenerative hyperplasia from other Diseases== | ||
* Nodular regenerative hyperplasia must be differentiated from other diseases that cause fatigue, hematemesis, and weight-loss such as:<ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> | * Nodular regenerative hyperplasia must be differentiated from other diseases that cause fatigue, hematemesis, and weight-loss such as:<ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> | ||
**[[Hepatocellular carcinoma]] | **[[Hepatocellular carcinoma]] | ||
** Hepatic adenoma, | ** Hepatic adenoma, | ||
** [[Focal nodular hyperplasia]] | **[[Focal nodular hyperplasia]] | ||
** [[Cirrhosis]] | **[[Cirrhosis]] | ||
** [[Peptic ulcer]] | **[[Peptic ulcer]] | ||
** [[Metastatic disease]] | **[[Schistosomiasis]] | ||
**[[Metastatic disease]] | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
| Line 62: | Line 72: | ||
===Age=== | ===Age=== | ||
* Nodular regenerative hyperplasia is more commonly observed among patients aged between 25 and 65 years old.<ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> | * Nodular regenerative hyperplasia is more commonly observed among patients aged between 25 and 65 years old.<ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> | ||
* Nodular regenerative hyperplasia is more commonly observed among adults and elderly patients | * Nodular regenerative hyperplasia is more commonly observed among adults and elderly patients. | ||
===Gender=== | ===Gender=== | ||
* | * It affects men and women equally, however in patients receiving AZA a weak association has been reported with the male sex.<ref name=":0">{{Cite journal|last=Seksik|first=P.|date=Feb 2011|title=Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine|url=https://www.ncbi.nlm.nih.gov/pubmed/20848502/|journal=Inflammatory Bowel Diseases|volume=|pages=|via=}}</ref> | ||
===Race=== | ===Race=== | ||
| Line 77: | Line 87: | ||
**common variable immune deficiency (CVID) | **common variable immune deficiency (CVID) | ||
**chronic granulomatous disease. | **chronic granulomatous disease. | ||
* | *Small bowel resection.<ref name=":0" /> | ||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
| Line 83: | Line 93: | ||
*An unexplained drop in platelets. | *An unexplained drop in platelets. | ||
* Early clinical features include [[fatigue]], [[weight loss]], and [[abdominal distension]]. | * Early clinical features include [[fatigue]], [[weight loss]], and [[abdominal distension]]. | ||
* If left untreated, the majority of patients with nodular regenerative hyperplasia may progress to develop [[Acute liver failure|acute hepatic failure]] or liver | * If left untreated, the majority of patients with nodular regenerative hyperplasia may progress to develop [[Acute liver failure|acute hepatic failure]] or liver decompensation and eventually requiring liver transplantation.<ref name="pmid7665869">{{cite journal| author=Bernard PH, Le Bail B, Cransac M, Barcina MG, Carles J, Balabaud C et al.| title=Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. | journal=J Hepatol | year= 1995 | volume= 22 | issue= 4 | pages= 495-9 | pmid=7665869 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7665869 }}</ref><ref name="pmid17414109">{{cite journal| author=Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD| title=Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. | journal=Am J Surg Pathol | year= 2007 | volume= 31 | issue= 4 | pages= 607-14 | pmid=17414109 | doi=10.1097/01.pas.0000213425.76621.f1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17414109 }}</ref> | ||
* | * Screening for the hepatocellular carcinoma is not recommended in these patients.<ref name="pmid17530368">{{cite journal| author=Isobe Y, Yamasaki T, Yokoyama Y, Kurokawa F, Hino K, Sakaida I| title=Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. | journal=J Gastroenterol | year= 2007 | volume= 42 | issue= 5 | pages= 407-9 | pmid=17530368 | doi=10.1007/s00535-007-2025-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17530368 }}</ref><ref name="pmid15740501">{{cite journal| author=Hidaka H, Ohbu M, Kokubu S, Shibuya A, Saigenji K, Okayasu I| title=Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers. | journal=J Gastroenterol Hepatol | year= 2005 | volume= 20 | issue= 3 | pages= 493-4 | pmid=15740501 | doi=10.1111/j.1440-1746.2005.03771.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15740501 }}</ref><ref name="pmid8633575">{{cite journal| author=Nzeako UC, Goodman ZD, Ishak KG| title=Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. | journal=Am J Gastroenterol | year= 1996 | volume= 91 | issue= 5 | pages= 879-84 | pmid=8633575 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8633575 }}</ref> | ||
* Nodular regenerative hyperplasia severity may be classified by the [[Child-Pugh score]]. | * Nodular regenerative hyperplasia severity may be classified by the [[Child-Pugh score]]. | ||
* Common complications of nodular regenerative hyperplasia, may include:<ref name="pmid20075739">{{cite journal |vauthors=Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ, Campbell S |title=Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series |journal=Eur J Gastroenterol Hepatol |volume=22 |issue=8 |pages=1001–5 |year=2010 |pmid=20075739 |doi=10.1097/MEG.0b013e3283360021 |url=}}</ref> | * Common complications of nodular regenerative hyperplasia, may include:<ref name="pmid20075739">{{cite journal |vauthors=Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ, Campbell S |title=Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series |journal=Eur J Gastroenterol Hepatol |volume=22 |issue=8 |pages=1001–5 |year=2010 |pmid=20075739 |doi=10.1097/MEG.0b013e3283360021 |url=}}</ref> | ||
| Line 94: | Line 104: | ||
==Diagnosis == | ==Diagnosis == | ||
===Diagnostic Criteria=== | ===Diagnostic Criteria=== | ||
* The diagnosis of nodular regenerative hyperplasia is made with the following | * The diagnosis of nodular regenerative hyperplasia is made with a strict diagnostic criteria, all of the following must be present:<ref name="livertox">Nodular regenerative hyperplasia http://livertox.nih.gov/Phenotypes_nodular.html Accesed on April 12, 2016</ref> | ||
** Latency of more than 6 months | ** Latency of more than 6 months | ||
** Minimal or no elevations in serum ALT | ** Minimal or no elevations in serum ALT | ||
| Line 104: | Line 114: | ||
***[[Varices]] (esophageal or gastric) | ***[[Varices]] (esophageal or gastric) | ||
***[[Portal hypertensive gastropathy]] | ***[[Portal hypertensive gastropathy]] | ||
* Liver biopsy excluding cirrhosis; showing nodularity with minimal or no fibrosis. | ** Liver biopsy excluding cirrhosis; showing nodularity with minimal or no fibrosis. Presence of fibrous septa definitely excludes NRH. | ||
*Definite exclusion of all other causes of portal hypertension | **Definite exclusion of all other causes of portal hypertension. | ||
**Confirmation of patent hepatic venous system on imaging. | |||
=== Symptoms === | === Symptoms === | ||
| Line 147: | Line 158: | ||
*** Less than <345 U/L: <3 times upper limit of normal | *** Less than <345 U/L: <3 times upper limit of normal | ||
** Decreased levels of vitamin B12<ref name="pmid22918688">{{cite journal| author=Goel A, Ramakrishna B, Muliyil J, Madhu K, Sajith KG, Zachariah U et al.| title=Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. | journal=Dig Dis Sci | year= 2013 | volume= 58 | issue= 1 | pages= 179-87 | pmid=22918688 | doi=10.1007/s10620-012-2361-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22918688 }}</ref> | ** Decreased levels of vitamin B12<ref name="pmid22918688">{{cite journal| author=Goel A, Ramakrishna B, Muliyil J, Madhu K, Sajith KG, Zachariah U et al.| title=Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. | journal=Dig Dis Sci | year= 2013 | volume= 58 | issue= 1 | pages= 179-87 | pmid=22918688 | doi=10.1007/s10620-012-2361-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22918688 }}</ref> | ||
**Liver biochemistry profile showing cholestasis, thought to be secondary to increased sinusoidal pressure.<ref>{{Cite journal|last=Pai|first=RK|date=2010|title=Aberrant expression of cytokeratin 7 in perivenular hepatocytes correlates with a cholestatic chemistry profile in patients with heart failure.|url=|journal=Modern pathology|volume=23|pages=1650-1656|via=}}</ref> | |||
===Imaging Findings=== | ===Imaging Findings=== | ||
| Line 154: | Line 166: | ||
** MRI scan | ** MRI scan | ||
* Ultrasound is the imaging modality of choice for nodular regenerative hyperplasia | * Ultrasound is the imaging modality of choice for nodular regenerative hyperplasia | ||
* On ultrasound | * On ultrasound: | ||
** May resemble the ring-shaped coral,an appearance first described in 2011.<ref name="pmid21697407">{{cite journal| author=Caturelli E, Ghittoni G, Ranalli TV, Gomes VV| title=Nodular regenerative hyperplasia of the liver: coral atoll-like lesions on ultrasound are characteristic in predisposed patients. | journal=Br J Radiol | year= 2011 | volume= 84 | issue= 1003 | pages= e129-34 | pmid=21697407 | doi=10.1259/bjr/17975057 | pmc=3473481 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21697407 }}</ref><ref name="XiangHan2018">{{cite journal|last1=Xiang|first1=Hao|last2=Han|first2=Jason|last3=Ridley|first3=William E|last4=Ridley|first4=Lloyd J|title=Liver atoll sign: Nodular regenerative hyperplasia|journal=Journal of Medical Imaging and Radiation Oncology|volume=62|year=2018|pages=88–88|issn=17549477|doi=10.1111/1754-9485.35_12784}}</ref> | ** May resemble the ring-shaped coral,an appearance first described in 2011.<ref name="pmid21697407">{{cite journal| author=Caturelli E, Ghittoni G, Ranalli TV, Gomes VV| title=Nodular regenerative hyperplasia of the liver: coral atoll-like lesions on ultrasound are characteristic in predisposed patients. | journal=Br J Radiol | year= 2011 | volume= 84 | issue= 1003 | pages= e129-34 | pmid=21697407 | doi=10.1259/bjr/17975057 | pmc=3473481 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21697407 }}</ref><ref name="XiangHan2018">{{cite journal|last1=Xiang|first1=Hao|last2=Han|first2=Jason|last3=Ridley|first3=William E|last4=Ridley|first4=Lloyd J|title=Liver atoll sign: Nodular regenerative hyperplasia|journal=Journal of Medical Imaging and Radiation Oncology|volume=62|year=2018|pages=88–88|issn=17549477|doi=10.1111/1754-9485.35_12784}}</ref> | ||
** Usually smaller than 3 mm | ** Usually smaller than 3 mm | ||
** Round isoechoic lesions | ** Round isoechoic or hypoechoic lesions | ||
** Thin hyper-echoic rim | ** Thin hyper-echoic rim | ||
* CT scan suggestive of nonspecifically hypodense nodules without significant enhancement. | * CT scan suggestive of nonspecifically hypodense nodules without significant enhancement. | ||
* MRI suggestive of Isointense nodules on T2-weighted images that contain foci of high intensity on T1-weighted images | * MRI suggestive of Isointense nodules on T2-weighted images that contain foci of high intensity on T1-weighted images | ||
=== Other Diagnostic Studies === | === Other Diagnostic Studies === | ||
* Nodular regenerative hyperplasia | * Nodular regenerative hyperplasia is definitely diagnosed using biopsy. | ||
* | ** Findings include:<ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> | ||
* | *** Diffuse fine nodularity of the liver | ||
** Diffuse fine nodularity of the liver | *** Nodule size between 1-3 mm | ||
** Nodule size between 1-3 mm | *** Mild hepatomegaly | ||
** Mild hepatomegaly | |||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
* There is no specific treatment for nodular regenerative hyperplasia. | * There is no specific treatment for nodular regenerative hyperplasia. | ||
* | * Mainstay therapy is preventing the progression of the disease (e.g., cessation of causative medication, treatment of the underlying conditions)<ref name="pmid16607155">{{cite journal| author=Seiderer J, Zech CJ, Diebold J, Schoenberg SO, Brand S, Tillack C et al.| title=Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. | journal=Eur J Gastroenterol Hepatol | year= 2006 | volume= 18 | issue= 5 | pages= 553-5 | pmid=16607155 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16607155 }}</ref> <ref name="pmid8020909">{{cite journal| author=Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R| title=Nodular regenerative hyperplasia of the liver graft after liver transplantation. | journal=Hepatology | year= 1994 | volume= 20 | issue= 1 Pt 1 | pages= 88-94 | pmid=8020909 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8020909 }}</ref> with acute management of complications, such as variceal bleeding. <ref name="pmid21472097">{{cite journal |vauthors=Hartleb M, Gutkowski K, Milkiewicz P |title=Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension |journal=World J. Gastroenterol. |volume=17 |issue=11 |pages=1400–9 |year=2011 |pmid=21472097 |pmc=3070012 |doi=10.3748/wjg.v17.i11.1400 |url=}}</ref> | ||
* Variceal bleeding in nodular regenerative hyperplasia can be treated in the same manner as variceal bleeding in cirrhotic portal hypertension by:<ref name="pmid24155091">{{cite journal| author=Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A et al.| title=Idiopathic portal hypertension: natural history and long-term outcome. | journal=Hepatology | year= 2014 | volume= 59 | issue= 6 | pages= 2276-85 | pmid=24155091 | doi=10.1002/hep.26904 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24155091 }}</ref><ref name="pmid26799606">{{cite journal| author=Noronha Ferreira C, Seijo S, Plessier A, Silva-Junior G, Turon F, Rautou PE et al.| title=Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. | journal=Hepatology | year= 2016 | volume= 63 | issue= 5 | pages= 1640-50 | pmid=26799606 | doi=10.1002/hep.28466 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26799606 }}</ref> | * Variceal bleeding in nodular regenerative hyperplasia can be treated in the same manner as variceal bleeding in cirrhotic portal hypertension by:<ref name="pmid24155091">{{cite journal| author=Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A et al.| title=Idiopathic portal hypertension: natural history and long-term outcome. | journal=Hepatology | year= 2014 | volume= 59 | issue= 6 | pages= 2276-85 | pmid=24155091 | doi=10.1002/hep.26904 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24155091 }}</ref><ref name="pmid26799606">{{cite journal| author=Noronha Ferreira C, Seijo S, Plessier A, Silva-Junior G, Turon F, Rautou PE et al.| title=Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. | journal=Hepatology | year= 2016 | volume= 63 | issue= 5 | pages= 1640-50 | pmid=26799606 | doi=10.1002/hep.28466 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26799606 }}</ref> | ||
** Use of non selective B blockers | ** Use of non selective B blockers | ||
** Endoscopic | ** Endoscopic variceal ligation | ||
=== Surgery === | === Surgery === | ||
Revision as of 07:18, 10 December 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Synonyms and keywords: NRHL; Non-cirrhotic portal hypertension; NRH
Overview
Nodular regenerative hyperplasia is described as a rare form of non-cirrhotic portal hypertension in the absence of a recognizable cause. Nodular regenerative hyperplasia is associated with solid organ transplant (eg. renal transplants, bone marrow transplants) and chronic use of medications. Nodular regenerative hyperplasia may be classified into 2 subtypes: pre-sinusoidal and sinusoidal.[1] The pathogenesis of nodular regenerative hyperplasia is characterized by arterial hypervascularity secondary to loss of hepatic vein radicles and loss of central venule in the hepatic lobule. Nodular regenerative hyperplasia is a rare disease. The estimated incidence of nodular regenerative hyperplasia is approximately 0.34 cases per 100,000 individuals. Nodular regenerative hyperplasia is more commonly observed among patients between 25 and 65 years old.[2] The majority of patients with nodular regenerative hyperplasia may be initially asymptomatic. Early clinical features include fatigue, weight loss, and abdominal distension. If left untreated, the majority of patients with nodular regenerative hyperplasia may progress to develop acute hepatic failure and death. The diagnosis of nodular regenerative hyperplasia is made with the following diagnostic criteria: latency of more than 6 months, minimal or no elevations in serum ALT, clinical, radiologic or endoscopic signs of portal hypertension, and liver biopsy.
Historical Perspective
- In 1953, the first case of Nodular regenerative hyperplasia was described by Ranstrom in a patient with Felty’s syndrome,and termed it as “miliary hepatocellular adenomatatosis”.
- Nodular regenerative hyperplasia was first described by Steiner in 1959.[3]
Classification
- Nodular regenerative hyperplasia may be classified into 2 subtypes:[1]
- Pre-sinusoidal
- Sinusoidal
- Other variant of nodular regenerative hyperplasia may include Banti's syndrome.
Pathophysiology
- It is a poorly understood disease process thought to be mediated by chronic inflammatory and thrombotic processes leading to occlusion of hepatic microvascuature.[4]
- The pathogenesis of nodular regenerative hyperplasia is characterized by:
- Arterial hypervascularity secondary to loss of hepatic vein radicles
- Loss of central venule in the hepatic lobule.
- The RASSF1A gene has been associated with the development of nodular regenerative hyperplasia, involving the proapoptotic pathway.[5]
- On gross pathology:[5]
- Diffuse nodularity
- On microscopic histopathological analysis:[5]
- Diffuse hepatic micronodular transformation in groups without fibrous septa between the nodules
- "Plump" hepatocytes surrounded by atrophic ones
- No fibrosis
Causes
- Common causes of nodular regenerative hyperplasia, may include:[6][7]
- Solid organ transplantation
- Autoimmune
- Infectious like HIV[8]
- Hematological
- Neoplastic
- Chronic use of medications, such as:
- NRH is commonly found in patients with Abernethy’s Syndrome.
Differentiating nodular regenerative hyperplasia from other Diseases
- Nodular regenerative hyperplasia must be differentiated from other diseases that cause fatigue, hematemesis, and weight-loss such as:[2]
Epidemiology and Demographics
- Nodular regenerative hyperplasia is a rare disease.
- The prevalence of nodular regenerative hyperplasia is approximately 31 cases per 100,000 individuals in the United Kingdom.
- The estimated incidence of nodular regenerative hyperplasia is approximately 0.34 cases per 100,000 individuals.
Age
- Nodular regenerative hyperplasia is more commonly observed among patients aged between 25 and 65 years old.[2]
- Nodular regenerative hyperplasia is more commonly observed among adults and elderly patients.
Gender
- It affects men and women equally, however in patients receiving AZA a weak association has been reported with the male sex.[13]
Race
- There is no racial predilection for nodular regenerative hyperplasia.
Risk Factors
- Common risk factors in the development of nodular regenerative hyperplasia include chronic vascular and infectious complications such as in
- inflammatory bowel disease
- Crohn's disease
- cystic fibrosis
- common variable immune deficiency (CVID)
- chronic granulomatous disease.
- Small bowel resection.[13]
Natural History, Complications and Prognosis
- Initially asymptomatic.
- An unexplained drop in platelets.
- Early clinical features include fatigue, weight loss, and abdominal distension.
- If left untreated, the majority of patients with nodular regenerative hyperplasia may progress to develop acute hepatic failure or liver decompensation and eventually requiring liver transplantation.[14][15]
- Screening for the hepatocellular carcinoma is not recommended in these patients.[16][17][18]
- Nodular regenerative hyperplasia severity may be classified by the Child-Pugh score.
- Common complications of nodular regenerative hyperplasia, may include:[19]
- The prognosis of nodular regenerative hyperplasia is related to the consequences of portal hypertension and the severity of the associated diseases.Prognosis is generally poor, and the mean survival rate of patients with nodular regenerative hyperplasia is approximately 8.1 years.[19]
Diagnosis
Diagnostic Criteria
- The diagnosis of nodular regenerative hyperplasia is made with a strict diagnostic criteria, all of the following must be present:[20]
- Latency of more than 6 months
- Minimal or no elevations in serum ALT
- Alkaline phosphatase (<345 U/L: <3 times ULN)
- Clinical, radiologic or endoscopic signs of portal hypertension, such as:[20]
- Ascites
- Splenomegaly
- Portovenous collaterals
- Varices (esophageal or gastric)
- Portal hypertensive gastropathy
- Liver biopsy excluding cirrhosis; showing nodularity with minimal or no fibrosis. Presence of fibrous septa definitely excludes NRH.
- Definite exclusion of all other causes of portal hypertension.
- Confirmation of patent hepatic venous system on imaging.
Symptoms
- Symptoms of nodular regenerative hyperplasia may include the following:[20]
- Fatigue
- Weight loss
- Abdominal distension
- Nausea
- Hematemesis
Physical Examination
- Patients with nodular regenerative hyperplasia may be well-appearing, lethargic, or confused.
- Physical examination of the abdomen may be remarkable for:
Inspection
- Caput medusae
- Appearance of distended and engorged superficial epigastric veins
Auscultation
- Positive liver scratch test for enlarged liver size.
- Cruveilhier-Baumgarten murmur
- A venous hum in patients with portal hypertension
Percussion
- Dull percussion
Palpation
- Abdominal distention
- Tenderness in right upper quadrant
- Hepatomegaly
- Splenomegaly
- Other physical signs for nodular regenerative hyperplasia may include:
- Pallor
- Jaundice
- Plantar and palmar erythema
- Dermatographic urticaria, or "scratching marks"
- Muehrcke nails
- Terry nails, or "luekonychia"
Laboratory Findings
- Laboratory findings consistent with the diagnosis of nodular regenerative hyperplasia, may include:[21]
Imaging Findings
- Imaging studies useful for the diagnosis of nodular regenerative hyperplasia, may include:[2]
- Ultrasound ( doppler ultrasound)
- CT scan
- MRI scan
- Ultrasound is the imaging modality of choice for nodular regenerative hyperplasia
- On ultrasound:
- CT scan suggestive of nonspecifically hypodense nodules without significant enhancement.
- MRI suggestive of Isointense nodules on T2-weighted images that contain foci of high intensity on T1-weighted images
Other Diagnostic Studies
- Nodular regenerative hyperplasia is definitely diagnosed using biopsy.
- Findings include:[2]
- Diffuse fine nodularity of the liver
- Nodule size between 1-3 mm
- Mild hepatomegaly
- Findings include:[2]
Treatment
Medical Therapy
- There is no specific treatment for nodular regenerative hyperplasia.
- Mainstay therapy is preventing the progression of the disease (e.g., cessation of causative medication, treatment of the underlying conditions)[27] [28] with acute management of complications, such as variceal bleeding. [2]
- Variceal bleeding in nodular regenerative hyperplasia can be treated in the same manner as variceal bleeding in cirrhotic portal hypertension by:[29][30]
- Use of non selective B blockers
- Endoscopic variceal ligation
Surgery
- Surgery is the mainstay of therapy for nodular regenerative hyperplasia in case of failure of endoscpic sclerotherapy/endoscopic variceal ligation.Other indication of surgery include symptomatic hypersplenism.[31]
- TIPS is more suitable to treat and prevent refractory gastric variceal bleed in patients with NRH,however it is avoided in certain conditions such as:[32]
- Renal failure
- Ascites
- Promthrombic conditions like malignancy
- Organ transplantation
- Surgical resection is usually performed for patients with persistent pain or for lesions that are suspicious on radiological findings.
- Splenectomy can be done if symptomatic hypersplenism.
- Liver transplantation is rarely considered.[33][34]
Prevention
- There are no primary preventive measures available for nodular regenerative hyperplasia,however close surveillance of the patient with the risk factors is required for the early diagnosis and management of the condition.[35]
- In patients receiving neo-adjuvant (downstaging) therapy before resection of malignancy, it is generally recommended to keep the duration of chemotherapy to a minimum number of cycles.
References
- ↑ 1.0 1.1 Louwers LM, Bortman J, Koffron A, Stecevic V, Cohn S, Raofi V (2012). "Noncirrhotic Portal Hypertension due to Nodular Regenerative Hyperplasia Treated with Surgical Portacaval Shunt". Case Rep Med. 2012: 965304. doi:10.1155/2012/965304. PMC 3432362. PMID 22956964.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Hartleb M, Gutkowski K, Milkiewicz P (2011). "Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension". World J. Gastroenterol. 17 (11): 1400–9. doi:10.3748/wjg.v17.i11.1400. PMC 3070012. PMID 21472097.
- ↑ STEINER PE (1959). "Nodular regenerative hyperplasia of the liver". Am. J. Pathol. 35: 943–53. PMC 1934844. PMID 13834213.
- ↑ Vispo, E (May 2010). "Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings". AIDS.
- ↑ 5.0 5.1 5.2 Nodular regenerative hyperplasia. Libre Pathology https://librepathology.org/wiki/Medical_liver_disease#Nodular_regenerative_hyperplasia Accessed on April 12, 2015
- ↑ Hartleb M, Gutkowski K, Milkiewicz P (2011). "Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension". World J Gastroenterol. 17 (11): 1400–9. doi:10.3748/wjg.v17.i11.1400. PMC 3070012. PMID 21472097.
- ↑ Buffet C, Cantarovitch M, Pelletier G, Fabre M, Martin E, Charpentier B; et al. (1988). "Three cases of nodular regenerative hyperplasia of the liver following renal transplantation". Nephrol Dial Transplant. 3 (3): 327–30. PMID 3140108.
- ↑ Schiano TD, Kotler DP, Ferran E, Fiel MI (2007). "Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV". Am J Gastroenterol. 102 (11): 2536–40. doi:10.1111/j.1572-0241.2007.01428.x. PMID 17640321.
- ↑ Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D; et al. (2007). "Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine". Gut. 56 (10): 1404–9. doi:10.1136/gut.2006.114363. PMC 2000290. PMID 17504943.
- ↑ Dubinksy, MC (August 2003). "6-thioguanine can cause serious liver injury in inflammatory bowel disease patients". Gastroenterology. 125(2): 298–303.
- ↑ Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P; et al. (2009). "Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study". Clin Infect Dis. 49 (4): 626–35. doi:10.1086/603559. PMID 19589079.
- ↑ Lepelley, Marion (November–December 2018). "Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?" (PDF). Annals of Hepatology. 17: 1067–1071. line feed character in
|title=at position 44 (help) - ↑ 13.0 13.1 Seksik, P. (Feb 2011). "Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine". Inflammatory Bowel Diseases.
- ↑ Bernard PH, Le Bail B, Cransac M, Barcina MG, Carles J, Balabaud C; et al. (1995). "Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation". J Hepatol. 22 (4): 495–9. PMID 7665869.
- ↑ Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD (2007). "Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis". Am J Surg Pathol. 31 (4): 607–14. doi:10.1097/01.pas.0000213425.76621.f1. PMID 17414109.
- ↑ Isobe Y, Yamasaki T, Yokoyama Y, Kurokawa F, Hino K, Sakaida I (2007). "Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension". J Gastroenterol. 42 (5): 407–9. doi:10.1007/s00535-007-2025-0. PMID 17530368.
- ↑ Hidaka H, Ohbu M, Kokubu S, Shibuya A, Saigenji K, Okayasu I (2005). "Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers". J Gastroenterol Hepatol. 20 (3): 493–4. doi:10.1111/j.1440-1746.2005.03771.x. PMID 15740501.
- ↑ Nzeako UC, Goodman ZD, Ishak KG (1996). "Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship". Am J Gastroenterol. 91 (5): 879–84. PMID 8633575.
- ↑ 19.0 19.1 Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ, Campbell S (2010). "Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series". Eur J Gastroenterol Hepatol. 22 (8): 1001–5. doi:10.1097/MEG.0b013e3283360021. PMID 20075739.
- ↑ 20.0 20.1 20.2 Nodular regenerative hyperplasia http://livertox.nih.gov/Phenotypes_nodular.html Accesed on April 12, 2016
- ↑ Seijo S, Lozano JJ, Alonso C, Reverter E, Miquel R, Abraldes JG, Martinez-Chantar ML, Garcia-Criado A, Berzigotti A, Castro A, Mato JM, Bosch J, Garcia-Pagan JC (2013). "Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension". Am. J. Gastroenterol. 108 (6): 926–32. doi:10.1038/ajg.2013.11. PMID 23419380.
- ↑ Naber AH, Van Haelst U, Yap SH (1991). "Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients". J Hepatol. 12 (1): 94–9. PMID 2007779.
- ↑ Goel A, Ramakrishna B, Muliyil J, Madhu K, Sajith KG, Zachariah U; et al. (2013). "Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis". Dig Dis Sci. 58 (1): 179–87. doi:10.1007/s10620-012-2361-7. PMID 22918688.
- ↑ Pai, RK (2010). "Aberrant expression of cytokeratin 7 in perivenular hepatocytes correlates with a cholestatic chemistry profile in patients with heart failure". Modern pathology. 23: 1650–1656.
- ↑ Caturelli E, Ghittoni G, Ranalli TV, Gomes VV (2011). "Nodular regenerative hyperplasia of the liver: coral atoll-like lesions on ultrasound are characteristic in predisposed patients". Br J Radiol. 84 (1003): e129–34. doi:10.1259/bjr/17975057. PMC 3473481. PMID 21697407.
- ↑ Xiang, Hao; Han, Jason; Ridley, William E; Ridley, Lloyd J (2018). "Liver atoll sign: Nodular regenerative hyperplasia". Journal of Medical Imaging and Radiation Oncology. 62: 88–88. doi:10.1111/1754-9485.35_12784. ISSN 1754-9477.
- ↑ Seiderer J, Zech CJ, Diebold J, Schoenberg SO, Brand S, Tillack C; et al. (2006). "Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy". Eur J Gastroenterol Hepatol. 18 (5): 553–5. PMID 16607155.
- ↑ Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R (1994). "Nodular regenerative hyperplasia of the liver graft after liver transplantation". Hepatology. 20 (1 Pt 1): 88–94. PMID 8020909.
- ↑ Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A; et al. (2014). "Idiopathic portal hypertension: natural history and long-term outcome". Hepatology. 59 (6): 2276–85. doi:10.1002/hep.26904. PMID 24155091.
- ↑ Noronha Ferreira C, Seijo S, Plessier A, Silva-Junior G, Turon F, Rautou PE; et al. (2016). "Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis". Hepatology. 63 (5): 1640–50. doi:10.1002/hep.28466. PMID 26799606.
- ↑ Sarin SK, Kapoor D (2002). "Non-cirrhotic portal fibrosis: current concepts and management". J Gastroenterol Hepatol. 17 (5): 526–34. PMID 12084024.
- ↑ Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L; et al. (2016). "Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension". Hepatology. 64 (1): 224–31. doi:10.1002/hep.28547. PMID 26990687.
- ↑ Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD (2007). "Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis". Am J Surg Pathol. 31 (4): 607–14. doi:10.1097/01.pas.0000213425.76621.f1. PMID 17414109.
- ↑ Elariny HA, Mizrahi SS, Hayes DH, Boudreaux JP, Hussey JL, Farr GH (1994). "Nodular regenerative hyperplasia: a controversial indication for orthotopic liver transplantation". Transpl Int. 7 (4): 309–13. PMID 7916934.
- ↑ Hartleb, Marek (2011). "Nodular regenerative hyperplasia: Evolving concepts on underdiagnosed cause of portal hypertension". World Journal of Gastroenterology. 17 (11): 1400. doi:10.3748/wjg.v17.i11.1400. ISSN 1007-9327.